Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
May 05, 2022 09:00 ET
|
Cassava Sciences, Inc.
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:...
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
April 25, 2022 09:00 ET
|
Cassava Sciences, Inc.
- Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology...
Webcast Details for Cassava Sciences’ Upcoming Fireside Chat
April 04, 2022 09:00 ET
|
Cassava Sciences, Inc.
– All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5th, 9am ET – AUSTIN, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a...
Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th
March 30, 2022 09:00 ET
|
Cassava Sciences, Inc.
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions via Email – – Fireside Chat Will Be Open to The Public via Webcast – AUSTIN,...
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
February 28, 2022 16:03 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients
February 10, 2022 16:07 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and...
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease
December 23, 2021 09:00 ET
|
Cassava Sciences, Inc.
New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants.Rethink-ALZ.com connects patients with nearest participating clinical site.Phase 3...
Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication
December 21, 2021 09:30 ET
|
Cassava Sciences, Inc.
Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This...
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
November 18, 2021 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s...
Cassava Sciences Reports Third Quarter 2021 Financial Results
November 10, 2021 09:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...